69
Views
0
CrossRef citations to date
0
Altmetric
Research Article

The prognostic value of age-adjusted Charlson comorbidity index in laparoscopic resection for hilar cholangiocarcinoma

, , , , , , , & show all
Pages 333-343 | Received 05 Sep 2023, Accepted 15 Nov 2023, Published online: 29 Nov 2023

References

  • Inchingolo R, Acquafredda F, Ferraro V, et al. Non-surgical treatment of hilar cholangiocarcinoma. WJGO. 2021;13(11):1696–1708. doi: 10.4251/wjgo.v13.i11.1696.
  • Ito F, Cho CS, Rikkers LF, et al. Hilar cholangiocarcinoma: current management. Annals of Surgery. 2009;250(2):210–218. doi: 10.1097/SLA.0b013e3181afe0ab.
  • Sapisochin G, Ivanics T, Subramanian V, et al. Multidisciplinary treatment for hilar and intrahepatic cholangiocarcinoma: a review of the general principles. Int J Surg. 2020;82S:77–81. doi: 10.1016/j.ijsu.2020.04.067.
  • Elvevi A, Laffusa A, Scaravaglio M, et al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol. 2022;27(5):100737. doi: 10.1016/j.aohep.2022.100737.
  • Rocha FG, Matsuo K, Blumgart LH, et al. Hilar cholangiocarcinoma: the memorial sloan-kettering cancer center experience. J Hepato Biliary Pancreat. 2010;17(4):490–496. doi: 10.1007/s00534-009-0205-4.
  • Saxena A, Chua TC, Chu FC, et al. Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival. Am J Surg. 2011;202(3):310–320. doi: 10.1016/j.amjsurg.2010.08.041.
  • Liu Z-P, Chen W-Y, Zhang Y-Q, et al. Postoperative morbidity adversely impacts oncological prognosis after curative resection for hilar cholangiocarcinoma. WJG. 2022;28(9):948–960. doi: 10.3748/wjg.v28.i9.948.
  • Tran TB, Ethun CG, Pawlik TM, et al. Actual 5-year survivors after surgical resection of hilar cholangiocarcinoma. Ann Surg Oncol. 2019;26(2):611–618. doi: 10.1245/s10434-018-7075-4.
  • Yasuta S, Sugimoto M, Kudo M, et al. Early postoperative decrease of skeletal muscle mass predicts recurrence and poor survival after surgical resection for perihilar cholangiocarcinoma. BMC Cancer. 2022;22(1):1358. doi: 10.1186/s12885-022-10453-2.
  • Jingdong L, Yongfu X, Yang G, et al. Minimally invasive surgery for hilar cholangiocarcinoma: a multicenter retrospective analysis of 158 patients. Surg Endosc. 2021;35(12):6612–6622. doi: 10.1007/s00464-020-08161-8.
  • Hsiao C-Y, Yang P-C, Li X, et al. Clinical impact of irreversible electroporation ablation for unresectable hilar cholangiocarcinoma. Sci Rep. 2020;10(1):10883. doi: 10.1038/s41598-020-67772-2.
  • Hu H-J, Jin Y-W, Shrestha A, et al. Predictive factors of early recurrence after R0 resection of hilar cholangiocarcinoma: a single institution experience in China. Cancer Medicine. 2019;8(4):1567–1575. doi: 10.1002/cam4.2052.
  • Zhang D, Qi F, Sun W, et al. Influencing factors of biliary fistula after radical resection of hilar cholangiocarcinoma: a prospect cohort. Eur J Med Res. 2022;27(1):214. doi: 10.1186/s40001-022-00851-4.
  • Bird NTE, McKenna A, Dodd J, et al. Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma. The British Surg. 2018;105(11):1408–1416. doi: 10.1002/bjs.10921.
  • Akashi K, Ebata T, Mizuno T, et al. Surgery for perihilar cholangiocarcinoma from a viewpoint of age: is it beneficial to octogenarians in an aging society? Surgery. 2018;164(5):1023–1029. doi: 10.1016/j.surg.2018.05.051.
  • Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–1251. doi. doi: 10.1016/0895-4356(94)90129-5.
  • Takada Y, Kawashima H, Ohno E, et al. The impact of the age-adjusted Charlson comorbidity index as a prognostic factor for endoscopic papillectomy in ampullary tumors. J Gastroenterol. 2022;57(3):199–207. doi: 10.1007/s00535-022-01853-z.
  • Song J, Lin Y, Zhang J, et al. Effect of the age-adjusted Charlson comorbidity index on the survival of esophageal squamous cell carcinoma patients after radical esophagectomy. JCM. 2022;11(22):6737. doi: 10.3390/jcm11226737.
  • Shinkawa H, Tanaka S, Takemura S, et al. Predictive value of the age-adjusted charlson comorbidity index for outcomes after hepatic resection of hepatocellular carcinoma. World J Surg. 2020;44(11):3901–3914. doi: 10.1007/s00268-020-05686-w.
  • Lauterio A, De Carlis R, Centonze L, et al. Current surgical management of Peri-Hilar and intra-hepatic cholangiocarcinoma. Cancers. 2021;13(15):3657. doi: 10.3390/cancers13153657.
  • Chen Y, Xu Y, Zhang Y. Current status of laparoscopic radical hilar cholangiocarcinoma in Mainland China. BST. 2020;14(3):168–173. doi: 10.5582/bst.2020.03010.
  • He Y-G, Huang W, Ren Q, et al. Comparison of efficacy and safety between laparoscopic and open radical resection for hilar cholangiocarcinoma-a propensity score-matching analysis. Front Oncol. 2022;12:1004974. doi: 10.3389/fonc.2022.1004974.
  • Ma D, Wang W, Wang J, et al. Laparoscopic versus open surgery for hilar cholangiocarcinoma: a retrospective cohort study on short-term and long-term outcomes. Surg Endosc. 2022;36(6):3721–3731. doi: 10.1007/s00464-021-08686-6.
  • Pan Y, Liu Z-P, Dai H-S, et al. Development of a model based on the age-adjusted Charlson comorbidity index to predict survival for resected perihilar cholangiocarcinoma. World J Gastrointest Oncol. 2023;15(6):1036–1050. doi: 10.4251/wjgo.v15.i6.1036.
  • Zhou S, Zhang X-H, Zhang Y, et al. The age-adjusted charlson comorbidity index predicts prognosis in elderly cancer patients. CMAR. 2022;14:1683–1691. doi: 10.2147/CMAR.S361495.
  • Liu J, Li J, He J, et al. The age-adjusted Charlson comorbidity index predicts post-operative delirium in the elderly following thoracic and abdominal surgery: a prospective observational cohort study. Front Aging Neurosci. 2022;14:979119–979doi. doi: 10.3389/fnagi.2022.979119.
  • Kalaycı B, Erten YT, Akgün T, et al. The relationship of age-adjusted Charlson comorbidity ındex and diurnal variation of blood pressure. Clin Exp Hypertens . 2019;41:113–117. doi: 10.1080/10641963.2018.1445755.
  • Shuvy M, Zwas DR, Keren A, et al. The age-adjusted Charlson comorbidity index: a significant predictor of clinical outcome in patients with heart failure. European J Intern Med. 2020;73:103–104. doi: 10.1016/j.ejim.2019.12.030.
  • Asano T, Yamada S, Fujii T, et al. The Charlson age comorbidity index predicts prognosis in patients with resected pancreatic cancer. Int J Surg. 2017;39:169–175. doi: 10.1016/j.ijsu.2017.01.115.
  • Dias-Santos D, Ferrone CR, Zheng H, et al. The Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancer. Surgery. 2015;157(5):881–887. doi: 10.1016/j.surg.2014.12.006.
  • Aoyama T, Atsumi Y, Kawahara S, et al. The clinical impact of the age-adjusted Charlson comorbidity index on esophageal cancer patients who receive curative treatment. In Vivo. 2020;34:2783–2790. doi: 10.21873/invivo.12103.
  • Chen Q, Zhang R, Xing B, et al. Optimal surgical sequence for colorectal cancer liver metastases patients receiving colorectal cancer resection with simultaneous liver metastasis resection: a multicentre retrospective propensity score matching study. Int J Surg. 2022;106:106952. doi: 10.1016/j.ijsu.2022.106952.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.